ストックスクリーナーアプリを入手
3.76
5.32%
0.19
前日終値:
$3.57
開ける：
$3.57
24時間の取引高:
153.02K
Relative Volume:
1.52
時価総額：
$176.68M
収益：
-
当期純損益:
$-19.90M
株価収益率:
-7.0943
EPS:
-0.53
ネットキャッシュフロー:
$-19.80M
1週間 パフォーマンス:
-1.31%
1か月 パフォーマンス:
-8.74%
6か月 パフォーマンス:
-32.37%
1年 パフォーマンス:
+30.10%
1日の値動き範囲:
$3.55
$3.81
1週間の範囲:
$3.475
$3.99
52週間の値動き範囲:
$2.8302
$6.8184
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
DMAC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
3.76 | 176.68M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
DiaMedica Therapeutics Insiders Up US$4.1m On US$9.00m Investment - simplywall.st
Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World
Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews
Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World
Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target - Investing.com
H.C. Wainwright holds DiaMedica stock Buy rating, $10 target By Investing.com - Investing.com India
Transcript : DiaMedica Therapeutics Inc.Special Call - marketscreener.com
With 39% ownership, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have a lot riding on the company's future - Yahoo Finance
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - BioSpace
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 | DMAC Stock News - GuruFocus
14,581 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Balyasny Asset Management L.P. - Defense World
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on D - GuruFocus
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire
Research Analysts Offer Predictions for DMAC FY2025 Earnings - Defense World
Equities Analysts Offer Predictions for DMAC FY2029 Earnings - Defense World
DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds - MSN
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics reports annual meeting results By Investing.com - Investing.com Nigeria
DiaMedica Therapeutics reports annual meeting results - Investing.com
DiaMedica Elects Directors at Annual Meeting - TipRanks
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) Q1 2025 Earnings Call Highligh - GuruFocus
DiaMedica Therapeutics Reports Q1 2025 Financials and Trial Progress - TipRanks
DiaMedica Therapeutics Announces Poster Presentation at European - GuruFocus
DiaMedica Therapeutics Announces Poster Presentation At European Stroke Organisation ConferenceESOC 2025 - marketscreener.com
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference -- ESOC 2025 | DMAC Stock News - GuruFocus
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025 - Business Wire
DiaMedica (DMAC) Awaits Key Phase 2 Study Results for Preeclamps - GuruFocus
Earnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectations By Investing.com - Investing.com India
Transcript : DiaMedica Therapeutics Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: DiaMedica Therapeutics Q1 2025 earnings beat expectations - Investing.com Australia
Barclays PLC Takes Position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
Raymond James Financial Inc. Makes New Investment in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - BioSpace
DiaMedica Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
DiaMedica Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - TipRanks
DiaMedica Therapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights | DMAC Stock News - GuruFocus
DiaMedica Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Susquehanna International Group LLP Grows Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - The AM Reporter
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May - BioSpace
How To Trade (DMAC) - news.stocktradersdaily.com
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
Diamedica Therapeutics Inc (DMAC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Giuffre Randall Michael | Director |
Feb 13 '25 |
Option Exercise |
2.56 |
17,000 |
43,570 |
392,412 |
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):